Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvgart perioperative use in thymectomy for myasthenia gravis
ChiCTR2400087638Phase 4Recruiting
- Sponsor
- Shijiazhuang People’s Hospita
- Start
- Jul 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (2 arms), sponsored by Shijiazhuang People’s Hospita. Primary endpoints: Myasthenia Gravis Foundation of America (MGFA) clinical classification and Proportion of patients successfully extubated within 1 day post-thymectomy and not requiring re-intubation within 1 week. Started Jul 2024; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2400087638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087638.